Wisp Debuts Women-Centric Longevity Suite Via New Healthy Aging Vertical

As Demand for Longevity Care Surges, Wisp Introduces Science-Backed, Female-Focused Solutions to a Male-Dominated Industry

NEW YORK--(BUSINESS WIRE)--Wisp, the largest women’s telehealth company in the U.S., today announced its expansion into clinician-guided longevity care with the launch of its new Longevity and Healthy Aging category. The initial offering features five science-backed treatments - glutathione (nasal spray and injection), NAD+ (nasal spray and injection), and low-dose naltrexone (LDN) - which work to optimize your biology by fueling cellular energy and repair and recalibrate the immune system.

The launch comes on the heels of a national Wisp survey of nearly 2,000 women, which revealed a significant longevity gap. While 75 percent of respondents prioritize long-term health in their daily choices, nearly half remain uncertain about which interventions actually work for the female body. Despite 92 percent believing telehealth is vital for healthy aging, only 11 percent feel current digital tools provide a sense of control – highlighting the need for practical, credible, and accessible support.

While the broader longevity market has expanded quickly through biohacking trends and male-centric performance culture, women’s specific needs have been largely ignored. Women represent 80 percent of autoimmune diagnoses, and face disproportionate rates of chronic fatigue, and cognitive symptoms like brain fog, during perimenopause and menopause.

“As the telehealth market for treatments like NAD+ and glutathione becomes increasingly fragmented and expensive, women are being left behind,” said Monica Cepak, CEO of Wisp. “Women are navigating complex hormonal transitions and immune issues that don’t fit into a standard biohacking framework. We’re translating complex science into clear, clinician-guided plans that support women long before something escalates.”

The new vertical evolves Wisp’s digital care model into a comprehensive healthspan ecosystem. Patients receive:

• Asynchronous Consultations: Flexible access to expert care
• Clinician Oversight: Continuous monitoring and personalized treatment adjustments
• Preventative Focus: A shift toward lifecycle-based care that goes beyond traditional reproductive health

The launch also marks Wisp’s entry into peptides, positioning the company as a lifelong partner. By focusing on how women actually age, Wisp is moving beyond one-time prescriptions and towards preventative wellness.

"We are helping women take control of their healthspan, not just their lifespan,” said Dr. Shannon Chatham, Medical Director at Wisp. “This isn’t about chasing trends, it's about providing evidence-based, sustainable care that meets the real needs of women as they age."

Wisp’s future roadmap includes programs for mitochondrial support, cognitive health pathways, menopause-adjacent longevity care, and preventive diagnostics and monitoring. Through these expanded offerings, Wisp continues to redefine the aging experience for all women.

About Wisp:

Wisp is the largest pure play women’s telehealth provider in the U.S., serving 1.8 million patients nationwide. Offering discreet, online care and a comprehensive range of first-to-market products, Wisp addresses women’s health needs across every stage of life—from birth control to fertility, menopause, STI testing, at-home diagnostics, migraine, and longevity. Recognized by Inc. as Best in Business 2025, TIME as Best Inventions of 2025, and Clio as Best Campaign in Health Equity of 2025. Wisp is majority-owned by WELL Health Technologies Corp. Visit hellowisp.com or follow @hellowisp on social media.